[go: up one dir, main page]

EA201101330A1 - Замещенные пиримидины, предназначенные для лечения рака - Google Patents

Замещенные пиримидины, предназначенные для лечения рака

Info

Publication number
EA201101330A1
EA201101330A1 EA201101330A EA201101330A EA201101330A1 EA 201101330 A1 EA201101330 A1 EA 201101330A1 EA 201101330 A EA201101330 A EA 201101330A EA 201101330 A EA201101330 A EA 201101330A EA 201101330 A1 EA201101330 A1 EA 201101330A1
Authority
EA
Eurasian Patent Office
Prior art keywords
intended
cancer treatment
substituted pyrimidines
treatment
pyrimidines
Prior art date
Application number
EA201101330A
Other languages
English (en)
Inventor
Иоаннис Сапоунтзис
Даниель Кун
Хайнц Штадтмюллер
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201101330A1 publication Critical patent/EA201101330A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

В заявке описаны соединения общей формулы (1), в которой В, R-R, R, m и n определены в п.1 формулы изобретения, которые применимы для лечения заболеваний, характеризующихся чрезмерной или аномальной пролиферацией клеток, и их применение для такого лечения.
EA201101330A 2009-03-18 2010-03-17 Замещенные пиримидины, предназначенные для лечения рака EA201101330A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09155515 2009-03-18
EP10153211 2010-02-10
PCT/EP2010/053451 WO2010106097A1 (en) 2009-03-18 2010-03-17 Substituted pyrimidines for the treatment of cancer

Publications (1)

Publication Number Publication Date
EA201101330A1 true EA201101330A1 (ru) 2012-04-30

Family

ID=42111169

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201101330A EA201101330A1 (ru) 2009-03-18 2010-03-17 Замещенные пиримидины, предназначенные для лечения рака

Country Status (17)

Country Link
US (2) US20110071158A1 (ru)
EP (1) EP2408752B1 (ru)
JP (1) JP5628281B2 (ru)
KR (1) KR20110128927A (ru)
CN (1) CN102421762A (ru)
AR (1) AR076134A1 (ru)
AU (1) AU2010224881A1 (ru)
BR (1) BRPI1013618A2 (ru)
CA (1) CA2755759A1 (ru)
CL (1) CL2011002300A1 (ru)
EA (1) EA201101330A1 (ru)
IL (1) IL214746A0 (ru)
MX (1) MX2011009780A (ru)
TW (1) TW201043611A (ru)
UY (1) UY32494A (ru)
WO (1) WO2010106097A1 (ru)
ZA (1) ZA201105986B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090019011A (ko) * 2006-06-15 2009-02-24 베링거 인겔하임 인터내셔날 게엠베하 단백질 키나아제 ｃ-알파의 억제제로서의 2-아닐리노-4-(헤테로사이클릭)아미노-피리미딘
KR101860057B1 (ko) 2008-05-21 2018-05-21 어리어드 파마슈티칼스, 인코포레이티드 키나아제 억제제로서 포스포러스 유도체
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
JP5503012B2 (ja) * 2009-10-30 2014-05-28 カーディアック ペースメイカーズ， インコーポレイテッド 迷走神経サージと反応とを用いるペースメーカ
PT2576541T (pt) 2010-06-04 2016-07-08 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
SI3124483T1 (sl) 2010-11-10 2019-10-30 Genentech Inc Pirazol aminopirimidinski derivati kot modulatorji lrrk2
AU2012216893B2 (en) 2011-02-17 2016-08-11 Cancer Therapeutics Crc Pty Limited FAK inhibitors
AU2012216894B2 (en) 2011-02-17 2016-07-14 Cancer Therapeutics Crc Pty Limited Selective FAK inhibitors
EA201391626A1 (ru) 2011-05-04 2014-03-31 Ариад Фармасьютикалз, Инк. Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
WO2014074670A1 (en) * 2012-11-08 2014-05-15 Bristol-Myers Squibb Company ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα
SG11201505850WA (en) * 2013-02-08 2015-08-28 Celgene Avilomics Res Inc Erk inhibitors and uses thereof
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
TW201613892A (en) 2014-08-13 2016-04-16 Celgene Avilomics Res Inc Forms and compositions of an ERK inhibitor
CN106146468B (zh) * 2015-04-17 2020-12-01 杭州雷索药业有限公司 吡啶酮类蛋白激酶抑制剂
CN106478700B (zh) * 2015-08-26 2020-12-29 杭州雷索药业有限公司 硼基取代的苯胺类蛋白激酶抑制剂
KR101992621B1 (ko) 2017-12-07 2019-09-27 주식회사 온코빅스 암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물
AU2020300619A1 (en) 2019-07-03 2022-01-27 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69933680T2 (de) * 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
HU230394B1 (hu) * 1998-11-10 2016-04-28 Janssen Pharmaceutica N.V. HIV-vírus szaporodását gátló pirimidin-származékok
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
EP1392662B1 (de) * 2001-05-29 2009-01-07 Bayer Schering Pharma Aktiengesellschaft Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
DE50212771D1 (de) * 2001-10-17 2008-10-23 Boehringer Ingelheim Pharma Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
EP1470121B1 (en) * 2002-01-23 2012-07-11 Bayer HealthCare LLC Pyrimidine derivatives as rho-kinase inhibitors
AU2003278088A1 (en) * 2002-10-28 2004-05-25 Bayer Healthcare Ag Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
US20050113398A1 (en) * 2003-08-07 2005-05-26 Ankush Argade 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
CA2566531A1 (en) * 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
EP1598343A1 (de) * 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
US7521457B2 (en) * 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
EP1966207A2 (en) * 2005-12-21 2008-09-10 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
PE20080068A1 (es) * 2006-05-15 2008-03-17 Boehringer Ingelheim Int Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
CN101535276B (zh) * 2006-10-23 2013-08-28 赛福伦公司 作为ALK和c-MET抑制剂的2,4-二氨基嘧啶稠合双环衍生物

Also Published As

Publication number Publication date
BRPI1013618A2 (pt) 2016-04-19
ZA201105986B (en) 2012-08-29
UY32494A (es) 2010-10-29
WO2010106097A1 (en) 2010-09-23
AR076134A1 (es) 2011-05-18
KR20110128927A (ko) 2011-11-30
CA2755759A1 (en) 2010-09-23
US20110071158A1 (en) 2011-03-24
EP2408752A1 (en) 2012-01-25
JP2012520850A (ja) 2012-09-10
CL2011002300A1 (es) 2012-01-20
AU2010224881A1 (en) 2011-09-08
JP5628281B2 (ja) 2014-11-19
MX2011009780A (es) 2011-09-30
TW201043611A (en) 2010-12-16
IL214746A0 (en) 2011-11-30
CN102421762A (zh) 2012-04-18
EP2408752B1 (en) 2015-08-12
US20140051674A1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
EA201101330A1 (ru) Замещенные пиримидины, предназначенные для лечения рака
EA201100564A1 (ru) Антипролиферативные соединения
EA201100794A1 (ru) Замещенные пиримидины, предназначенные для лечения заболеваний, таких как рак
EA201201030A1 (ru) 5-алкинилпиримидины
EA201201661A1 (ru) Новые аминопиразолохиназолины
EA201000105A1 (ru) Химические соединения
EA201200552A1 (ru) Производные пиримидина в качестве ингибиторов протеинтирозинкиназы 2
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
EA201100255A1 (ru) 5-алкинилпиримидины
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
EA201400965A1 (ru) 6-алкилпиридины в качестве миметиков smac
UA97834C2 (ru) Производные сульфониламида для лечения анормального роста клеток
EA200800172A1 (ru) 2,4-диаминопиримидины как ингибиторы aurora
EA200801362A1 (ru) Пиримидинил бензотиофеновые соединения
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
EA201391106A1 (ru) Новые гетероциклические производные
EA201300610A1 (ru) Хиназолинкарбоксамидазетидины
EA201200218A1 (ru) Новые бициклические соединения мочевины
EA201100874A1 (ru) Соединения для лечения рака
UA112795C2 (uk) Біциклічні піразинонові похідні
EA201200247A1 (ru) Новые азагетероциклические соединения
EA201100254A1 (ru) Новые соединения